RE:RE:RE:New Press Release - Kane Biotech Receives Funding Support to Expand the revyve(TM) Antimicrobial Wound Gel FamilyHello KevinOleary, nice to hear from you!
I think that the Revyve line of products will be the cornerstone of this company since it is already FDA approved, the price point seems to be in-line with the market requirements and they are already expanding the offering. The OTC aproval was key to me, it is allowing KNE to search for commercial partners that are involved in the 'consumer goods' space which could lead to major increase in sales (if we find the right partners and product mix).
All of the above makes me think that Revyve will allow KNE to bring enough cash to support the lengthy approval process that DispersinB will have to go through -- we haven't started phase 1 yet so, there is a long way to go, still. Agree with you that Dispersin will eventually be THE product but for now, Revyve is what this company needs to not only survive but expand.
GLTA!